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1. Introduction 
Bradycardia due to high-degree atrioventricular (AV) block remains the main indication for 
permanent cardiac pacing in childhood. Although there are major differences in the etiology 
of AV block in children and adults, the same pacing systems and leads are used in both age 
groups. The first pacemaker was implanted in a child in the late 1960s (Martin et al., 1966). 
Nowadays, implantation of a permanent pacing system is a straightforward and safe 
procedure with excellent pacemaker performance during follow-up, even in infants and 
small children (Welisch et al., 2010). 
Applying permanent pacing therapy in the young can be challenging. Many paediatric 
issues, such as patient size, body growth, coexistence of congenital heart disease, presence of 
residual intracardiac shunts and life style, have to be considered. Selecting the best pacing 
system for a child requires a firm understanding of modern pacing design, pacing 
indications, advantages and drawbacks of epicardial and endocardial lead pacing, and 
possible complications. The aim of this chapter is to give a dedicated overview of the 
practical implications of pacing in children with complete AV block. 
2. Etiology of atrioventricular block in childhood 
Before we describe the techniques and management of pacing in children, an overview of 
the most important causes of complete AV block in children is given. Having a complete 
understanding of the etiology and prognosis of complete AV block in childhood should 
improve best pacing practice in the paediatric age group. A summary of the causes of 
complete AV block in childhood is presented in Table 1. 
2.1 Postoperative complete atrioventricular block 
Complete AV block is an important complication of surgical correction of congenital heart 
disease (Gross et al., 2006). Due to advances in surgical techniques and improved anatomic 
knowledge of the course of the conduction system in various congenital heart diseases, the 
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incidence of postoperative complete AV block has decreased significantly during the last 
decades (Gross et al., 2006). Although complete AV block was found in more than 10% of 
children in the 1960s, a study from the early 1970s reported that this incidence had fallen to 
around 2% (Fryda et al., 1970). In the current era, 1 – 3% of all children undergoing surgery 
for congenital heart disease develop complete AV block. Importantly, it has been shown that 
surgical complete AV block is associated with significant morbidity and decreased survival. 
(Gross et al., 2006; Driscoll et al., 1979). Therefore, all children should receive a pacemaker 
device when complete AV block does not resolve in the early postoperative course (Gross et 
al, 2006). 
Surgical acquired AV block     VSD, AVSD, TOF 
       LVOT obstruction,  
ccTGA 
       discordant AV connections 
 
Isolated congenital complete AV block    maternal anti-SSA/Ro – SSB/La antibodies, NLE 
       abnormal development of AV conduction 
 
AV block associated      ccTGA 
with structural cardiac abnormalities    heterotaxy, left atrial isomerism 
 
single ventricle physiology, Fontan palliation
 D-TGA after Mustard or Senning operation  
 
Infectious disease      bacterial 
       viral  
EBV, varicella, Coxsackie B  
Rheumatic fever 
      Chagas’ disease    
      Lyme disease 
       HIV  
 
Neuromuscular disease     Myotonic dystrophy 
      Emery-Dreifuss muscular dystrophy 
      Duchenne muscular dystrophy 
Metabolic disease      Carnitine deficieny 
      Kearns-Sayre syndrome 
Syndromes       Holt-Oram syndrome 
      18p-syndrome 
Others       long-QT syndrome   
       post-Ablation 
      hypertrophic cardiomyopathy 
      percutaneous VSD closure 
      myocarditis 
      connective tissue disease 
      sarcoidosis 
      amyloidosis 
      cardiac tumors 
 
AVSD = atrioventricular septal defect, AV = atrioventricular, ccTGA = congenitally corrected 
transposition of the great arteries, D-TGA = dextro-transposition of the great arteries, EBV = Ebstein-
Barr virus, HIV = human immunodeficiency virus, LVOT = left ventricular outflow tract, NLE = 
neonatal lupus erythematosus, TOF = tetralogy of Fallot, VSD = ventricular septal defect. 
Table 1. Causes of complete atrioventricular block in neonates, infants and children. 
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The greatest risk for complete AV block is associated with corrective surgical procedures for 
ventricular septal defects (VSD), usually as part of more complex congenital heart disease, 
atrioventricular septal defects (AVSD), left ventricular outflow tract obstruction, L 
transposition of the great arteries, tetralogy of Fallot (TOF), and discordant atrioventricular 
connections (Batra et al., 2003; Gross et al., 2006). Most children who require pacing for 
surgically induced AV block are less than 1 year old. 
Of importance, several studies report spontaneous resolution of complete AV block in the 
early postoperative period, most often occurring between 7 and 14 days. Complete AV block 
may resolve spontaneously in 43 – 92% of children (Gross et al, 2006). Factors associated 
with a spontaneous recovery of AV nodal function are currently not known. Hence, late 
recovery of complete AV block has also been reported in approximately 10% of cases (Batra 
et al., 2003). Recovery of AV conduction was identified within the first 30-day postoperative 
interval in most children. Recurrence of high-degree AV block or complete AV block is not 
observed in these children, although different studies have shown inconsistent findings 
(Batra et al., 2003; Gross et al., 2006). On the contrary, late onset complete AV block (> 30 
days postoperatively) has been described after cardiac surgery for congenital heart disease 
(Goldman et al., 1985.; Liberman et al., 2008). Complete AV block was identified at a mean 
of 4.7 years after surgery in one study (Goldman et al., 1985), occurring as late as 16 years 
after cardiac surgery (Liberman et al., 2008). Close monitoring of AV conduction seems 
mandatory in all patients after surgery for congenital heart disease. 
2.2 Congenital complete AV block 
Congenital complete AV block (CCAVB) is a rare cardiac conduction disorder with an 
estimated incidence of 1 in 11.000 to 22.000 live births (Michaelson & Engle, 1972). In 25% of 
cases, coexisting congenital heart disease can be identified. Congenital heart diseases in 
which AV conduction is particularly at risk include heterotaxy syndrome with left atrial 
isomerism, atrioventricular septal defect with common atrioventricular junction, and 
congenitally corrected transposition of the great arteries (ccTGA) (Anderson et al., 1974; 
Stephenson & Kaltman, 2006). Complete AV block in these patients may be present at birth, 
or may develop later in life. When complete AV block is not present at birth, close 
monitoring of the cardiac conduction system is mandatory in these patients (Stephenson & 
Kaltman, 2006 & Graham et al, 2000). Notwithstanding, most patients with CCAVB have 
structurally normal hearts, and CCAVB in these cases is therefore referred to as ‘isolated’ 
CCAVB. Although abnormal embryological development of the cardiac conducting system 
have been identified as a cause of isolated CCAVB (Anderson et al., 1977; Lev et al., 1971), 
most patients have autoimmune, anti-SSA/Ro – SSB/La-antibody-induced CCAVB (Buyon & 
Winchester, 1990; McCue et al., 1977). 
Since an association between maternal connective tissue disease and anti-SSA/Ro – SSB/La 
antibodies was suggested in the late 1970s (McCue et al., 1977), efforts in clinical and 
experimental studies have resulted in a broad understanding of the pathogenesis and 
clinical outcome of autoimmune-associated CCAVB (Boutjdir et al., 1998; Buyon & Clancy, 
2005; Jaeggi et al., 2010). Maternal anti-SSA/Ro – SSB/La autoantibodies enter the fetal 
circulation between 16 and 24 weeks gestation (Buyon et al., 1995), and may induce injury to 
the developing cardiac conducting system and myocardial tissue in a subset of fetuses. 
Autoimmune CCAVB develops in 1 – 2% of these antibody-positive pregnancies. Of 
importance, the estimated recurrence risk of women who had a previous child with CCAVB 
is 16 – 25% (Buyon et al., 2009). Although 30 – 50% of these women have clinically manifest 
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connective tissue diseases, such as systemic lupus erythematosus or Sjögren’s syndrome, the 
majority of antibody-positive women who gave birth to an infant with CCAVB, are 
asymptomatic (Julkunen & Eronen, 2001). 
Anti-SSA/Ro – SSB/La antibody-induced CCAVB is associated with substantial morbidity 
and mortality during gestation and infancy, with more than 60% of infants requiring 
permanent pacemaker therapy in their first year of life (Buyon et al., 1998; Breur et al., 2002). 
The most common indication for pacemaker placement in the neonatal period is congestive 
heart failure (Buyon et al., 1998). The natural history of isolated CCAVB was addressed in a 
prospective multicenter study, involving 102 children and adults (Michaelsson et al., 1995; 
Michaelsson et al., 1997). All children were asymptomatic during their 15 years of life. Of 
concern, 10 patients without a pacemaker died, of which 6 CCAVB related deaths occurred 
without preceding symptoms. The mortality rate was significantly lower in paced compared to 
non-paced patients. Therefore, the authors concluded that the prognosis of isolated CCAVB 
may be improved when patients are paced earlier in life (Michaelsson et al., 1997). A recent 
study supported the concept of earlier ‘prophylactic’ pacing in children with isolated CCAVB 
(Balmer et al., 2002). At present, more than 94% of children with CCAVB are paced before they 
reach the age of 15 years (Villain et al., 2006). 
Another important prognostic issue in children with autoimmune-associated CCAVB is the 
development of dilated cardiomyopathy (Moak et al., 2001; Udink ten Cate et al., 2001). We 
and others have demonstrated that as many as 6 – 11 % of paced children with autoimmune-
associated CCAVB develop dilated cardiomyopathy during a follow-up period of 10 ± 7 
years (Moak et al., 2001; Udink ten Cate et al., 2001; Kim et al., 2007). Risk factors may 
include presence of anti-SSA/Ro – SSB/La antibodies, increased heart size at initial 
evaluation and the absence of pacemaker-associated normalization of left ventricular size 
during follow-up (Udink ten Cate et al., 2001). Although pacemaker-induced ventricular 
dysfunction has been offered as an etiologic factor in the pathogenesis of dilated 
cardiomyopathy in these patients (Janousek et al., 2004), some children with anti-SSA/Ro – 
SSB/La antibody-induced CCAVB develop dilated cardiomyopathy before being paced 
(Nield et al., 2002; Villain et al., 2006). These data suggest that children with anti-SSA/Ro – 
SSB/La antibody-induced CCAVB may have preexisting myocardial damage, which 
increases their risk of pacemakerinduced dilated cardiomyopathy. Close monitoring of their 
ventricular function during follow-up is mandatory. 
The prognosis of non-autoimmune CCAVB seems to be different compared to autoimmune-
associated CCAVB (Cruz et al., 2004; Villain et al., 2006). Patients are commonly diagnosed 
later in life, the AV block is often progressive, and these children have a good prognosis 
after pacemaker implantation (Villain et al, 2006). 
Moreover, connective tissue disease is not found in these mothers, and the recurrence risk in 
future pregnancies is low. Pacemaker-induced heart failure does not seem to occur during 
medium follow-up (Cruz et al., 2004). For these reasons, a new definition of congenital 
complete AV block was recently proposed: ‘an AV block is defined as congenital if it is 
diagnosed in utero, at birth or within the neonatal period’ (Brucato et al., 2003). 
3. Pacing indications and patient selection 
Specific recommendations for pacemaker implantation have been published in several 
guidelines by the American College of Cardiology, the American Heart Association, and the 
Heart Rhythm Society, with an update in 2008 (Epstein et al., 2008). The European Society of 
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Cardiology, and the European Heart Rhythm Association have also recently published a 
guideline for permanent pacing and cardiac resynchronization therapy (Vardas et al., 2007). 
Pacing recommendations for children are also a part of these published guidelines, and have 
been very useful in daily practice. It should be remembered however, that the level of evidence 
for these recommendations is low. Most recommendations for children requiring permanent 
pacing are not based on prospective clinical studies, but rather rely on expert opinion. 
The main indications for pacing in children are (1) symptomatic sinus node dysfunction, (2) 
bradycardia-tachycardia syndrome, (3) congenital, surgical or acquired complete AV block, 
and (4) advanced second-degree AV block. Because this chapter is dedicated to AV block in 
children, pacing recommendations for this specific conduction disorder are summarized in 
Table 2. 
 
 
 
 
Fig. 1. Rhythm strip showing complete atrioventricular block (A) and second-degree 
atrioventricular block in a 2-year-old boy with bradycardia-related symptoms (B). The child 
underwent permanent pacemaker implantation (single chamber) using the transvenous 
approach. A lumenless 4.1-F endocardial lead inserted. 
Surgical second-degree or complete AV block persisting beyond 7 days postoperatively, not 
expecting to resolve spontaneously, is considered to be a Class I indication for permanent 
pacemaker implantation (Vardas et al., 2007; Epstein et al., 2008). There are two important 
reasons for not delaying pacemaker implantation in these patients, although there is 
reasonable evidence that AV conduction may recover in the first 30 postoperative days 
(Batra et al., 2003). The prognosis of surgically induced complete AV block is poor (Gross et 
al, 2006, Simon et al., 1982). The second consideration is that there have been enormous 
improvements in pacing systems and battery longevity. A pacemaker can now be safely 
implanted in most small infants. 
Advanced second-degree or complete CAVB with symptomatic bradycardia (Figure 1), 
ventricular dysfunction, or low cardiac output, is also considered to be a Class I indication 
for pacemaker insertion. One has to keep in mind that symptoms of bradycardia can be 
subtle in children, (Balmer & Bauersfeld, 2003). Therefore, many investigators have tried to 
A 
B 
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predict the need for future pacemaker therapy in isolated CCAVB, using diagnostic tests, 
such as serial ECG recordings and ambulatory Holter monitoring (Esscher & Michaellson, 
1983; Dewey et al., 1987; Breur et al, 2006). Interpretation of these parameters remains 
difficult. 
 
 
Class I,  permanent pacemaker implantation is indicated for:  
 
1. Advanced 2nd or 3rd AV block with symptomatic bradycardia, ventricular dysfunction, or low cardiac out put. 
 
2. Postoperative advanced 2nd or 3rd degree AV block t hat is not expected to resolve or persists > 7 days  after 
cardiac surgery. 
 
3. Congenital complete AV block with a wide QRS escape  rhythm, complex ventricular ectopy, or ventricular 
dysfunction. 
 
4. Congenital complete AV block in the infant with a ventricular rate less than 55 betas per minute (bps ) or with 
congenital heart disease and a ventricular rate les s than 70 bps. 
 
Class IIa, permanent pacemaker implantation is reasonable for: 
 
1. Congenital complete AV block beyond the first year of life with an average heart rate less than 50 bp m, 
abrupt pauses in ventricular arte that are 2 or 3 times the basic cycle length, or associated with sym ptoms 
due to chronotropic incompetence. 
 
2. Congenital heart disease and impaired hemodynamics due to sinus bradycardia or loss of AV synchrony. 
 
3. Unexplained syncope in the patient with prior congenital heart surgery complicated by transient complete 
heart block with residual fascicular block after careful eveluation to exclude other causes of syncope . 
 
4. Long QT syndrome with 2:1 or complete AV block. 
 
Class IIb, permanent pacemaker implantation may be considered for: 
 
1. Transient postoperative third-degree AV block that reverts to sinus rhythm with residual bifascicular block. 
 
2. Congenital complete AV block in asymptomatic children or adolescents with an acceptable rate, narrow QRS 
complex, and normal ventricular function. 
 
3. Neuromuscular diseases with any degree of AV block (including first-degree AV block) due to risk of 
unpredictable progression of AV conduction disease. 
 
Class III,   permanent pacemaker implantation is not  indicated for:  
 
1. Transient postoperative third-degree AV block with return of normal AV conduction within 7 days. 
 
2. Asymptomatic postoperative bifascicular block with and without first-degree AV block. 
 
3. Asymptomatic type I (Wenckebach) second-degree AV b lock 
  
* Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for 
device-based therapy of cardic rhythm abnormalities: executive summary. Heart Rhythm 2008;5:e1-62; 
and Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization 
therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European 
Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur 
Heart J 2007;28:2256-2295. 
Table 2. Indications for permanent pacemaker implantation in children and adolescents with 
high-degree or complete AV block with or without congenital heart disease*. 
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Several studies have shown that monitoring of heart size and cardiomegaly in children with 
isolated CCAVB is of use in daily practice in deciding if a child requires a pacemaker 
(Beaufort-Krol et al., 2007; Breur et al., 2002; Sholler & Walsh, 1989). We favour implantation 
of a pacemaker in a child with isolated CCAVB in whom the heart size progresses during 
follow-up, even when the heart rate criteria for pacemaker implantation are not met. 
4. Selecting a pacing system: single or dual chamber device? 
The aim of permanent pacing therapy in patients with complete AV block is to restore heart 
rhythm and rate, relieve the patient from bradycardia-related symptoms, provide 
haemodynamic stability, and thereby improve patient well-being and clinical outcome. 
These objectives can only be met when the best of ‘two pacing worlds’ are combined: a 
single or dual chamber device with an epicardial or transvenous pacing lead. Selecting a 
pulse generator and pacing lead for a child who needs life-long pacing for complete AV 
block depends on several important factors. It should be remembered that the risks of 
pacemaker placement are related to the size of the patient, making patient size an important 
consideration in selecting an appropriate pacing system. Issues regarding the selection of a 
single or dual chamber are addressed in this part of the chapter. Considerations related to 
epicardial or endocardial lead system selection are subsequently discussed. 
4.1 Modern pulse generators: size and location of pacemaker pocket 
Many of the shortcomings of pacing in children have been overcome in the last two decades. 
Pulse generators have become smaller and battery longevity has increased. Also the 
programmability of many pulse generators has seen major advances. 
Due to these advances, pacemaker therapy can be applied safely to small infants and even 
preterm infants weighing less than 2000 g (Ohmi et al., 1992; Kammeraad et al 2004,; Inoue 
et al., 2005). Although most of these infants will receive a single chamber device (VVI mode) 
with an epicardial pacing lead because of their small size, single lead endocardial pacing 
systems also have been successfully implanted with an abdominally located pacemaker 
pocket (Hoorntje et al., 2000). 
The abdominal pocket is the preferred pulse generator location in neonates, infants and small 
children receiving an epicardial pacing system. Subpectoral and prepectoral subcutaneous 
pockets are used in children and adolescents for placement of their transvenous pacing 
system. In general, the subpectoral pocket is preferred in young active children in whom a 
pulse generator implanted in a prepectoral subcutaneous pocket is more prone to trauma. 
Moreover, the risk of deep pocket infections seem to be less when the pulse generator in 
inserted under the pectoralis major muscle (Gillette et al., 1991; Cohen et al., 2002). 
4.2 Programming a pacing device: heart rate limits and rate-responsive pacing 
Most modern pulse generators have a large flexibility in programming. Several pacemaker 
options are available which may help achieving better pacemaker performance, longevity, 
and optimize patient needs in daily life. 
Upper and lower heart rate settings are important in children. Physiologically, the average 
heart rates in children differ from the adult heart rate requirements. An upper heart rate 
limit of 180 beats per minute is required in most small children. The selected pulse generator 
should be capable of providing high upper rate limits. Another important topic is the 
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programmed minimal heart rate. Particularly in neonates and small infants, programming 
the heart rates in the normal physiological range may induce ventricular dysfunction (Chen 
et al., 2008). After programming a pacemaker in a specific heart rate range, these settings 
should be re-evaluated at every pacemaker follow-up visit. Pacemaker programming must 
be tailored to the individual paediatric patient. 
Another important function is the rate-responsive pacing mode. The advantage of rate-
responsive pacing lies in the presumed augmentation of cardiac output with exercise. 
Ideally, rate-responsive or rate-adaptive sensors in pacemakers sense changes in activity 
level and adapt heart rate to the new level of activity. An adequate chronotropic response to 
exercise has been demonstrated in adult patients with a VVIR pacing mode (Oldroyd et al., 
1991). Another study in adults showed that DDDR pacing resulted in a slight improvement 
in cardiopulmonary performance compared to VVIR pacing, probably due to a better atrial 
contribution to cardiac output on exercise in DDDR paced patients (Vogt et al, 1988). 
Although, a normal increase in heart rate during exercise is more important than AV 
synchrony, the addition of AV synchrony does provide an additional benefit, supporting the 
use of DDDR pacing mode in adults (Benditt et al., 1987). 
As with many topics in paediatric cardiology, results from large adult studies are often 
extrapolated to paediatric patients. However, limited data regarding rate-responsive pacing 
exist in children. One study showed that minute ventilation sensors, used for sensing the 
chronotropic response, closely matched intrinsic sinus node function during exercise in 
healthy children, supporting the appropriateness of rate-responsive pacing in children 
requiring permanent pacing therapy (Cabrera et al., 2002). Ventricular rate-responsive 
pacing is feasible, effective and safe in children with complete atrioventricular block 
(Ragonese, et al., 1994). Therefore, most pacemakers in children with complete AV block are 
programmed to a rate-responsive mode. 
4.3 Battery longevity and autocapture-controlled pacing 
In general, battery longevity is good with modern pacemakers. A pacemaker battery may last 
for 5 – 10 years in most paediatric patients (Udink ten Cate et al., 2002; Welisch et al., 2010). 
Battery survival is influenced by many factors, of which pacing mode, programmed heart rate, 
pacing lead performance, and percentage of cumulative stimulation are the most important 
(Maginot et al., 2000.; Batra & Balaji, 2006). The higher heart rate requirements of infants and 
children compared with adults result in less battery durability. Moreover, epicardial pacing 
systems, which are frequently implanted in infants and small children, have higher acute and 
chronic pacing thresholds, further limiting battery longevity (Khairy et al., 2006). 
An important tool in reducing energy drain and extending battery life in infants and 
children is the use of automatic algorithms for pacing threshold measurement, such as 
AutoCapture and Ventricular Capture Management (Bauersfeld et al, 1999; Cohen et al., 
2004; Silvetti et al, 2007a). These algorithms measure atrial and/or ventricular pacing 
thresholds throughout the day. The system responds to increases and decreases of pacing 
thresholds and subsequently regulates battery output. These pacing algorithms can be used 
in both epicardial and transvenous lead systems. A recent study demonstrated that 
autocapture pacing in children with epicardial lead systems extended the calculated battery 
life up to 15% (Tomaske et al, 2007). Automatic pacing threshold determination might be an 
important technological tool to prolong battery longevity and increase pacemaker safety. 
Patients with high or fluctuating pacing thresholds benefit the most. However, not all 
pacemakers are equipped with this function. 
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4.4. Single and dual chamber pacemakers 
The positive haemodynamic effects of AV synchronous pacing have been well described in 
adults. A properly timed atrial contraction, resulting in AV synchrony, augments 
ventricular filling and cardiac output through the Frank-Starling relationship, improves 
venous return, and assists AV closure (Buckingham et al., 1992). The value of AV synchrony 
was already recognized in the early 1970s in patients with AV block following cardiac 
surgery and acute myocardial infarcts (Chamberlain et al., 1970; Hartzler et al., 1977). 
While evidence exists that DDD pacing might be superior to VVI pacing in adults, no similar 
data are available in children, in whom a single chamber device offers the advantage of 
lower cost, ease of implantation and extended battery longevity. With AV asynchronous 
pacing, the atria may contract against closed AV valves, causing atrial distension with 
subsequent increases in pulmonary wedge pressure and jugular venous pressure 
(Horenstein et al., 2004). This might provoke signs and symptoms of fullness, dyspnea, 
headache, fatigue, syncope and exercise intolerance, the so-called pacemaker syndrome 
(Furman, 1994). 
Pacemaker syndrome however, is exceedingly uncommon in young children. The 
development of symptoms attributable to the pacemaker syndrome in children with single 
chamber devices is a time related event (Horenstein et al., 2003; Horenstein et al., 2004). 
Although more than 50% of children with single chamber devices may develop pacemaker 
syndrome, those children who became symptomatic had been paced for a median of 11 
years. These data were confirmed in another study (Horenstein et al., 2003). Based on these 
findings, single chamber pacing device is preferably implanted as the initial pacing mode in 
young children, particularly in those with a structurally normal heart, isolated complete AV 
block and normal ventricular function. Early establishment of AV synchrony in this patient 
population offers no added benefit. 
Some data exists on VDD pacing in children, a pacing mode which combines the advantages 
of AV synchrony and the smaller size of single chamber pacing systems (Rosenthal et al., 
1997a; Seiden et al., 1997). In this pacing mode, a single implanted transvenous lead is used 
for AV synchronous pacing, with the extra proximally located electrode being used for atrial 
sensing. The acute results of this pacing mode are similar to others used in the 
conventionally used pacing modes (Rosenthal et al., 1997a; Seiden et al., 1997). There are 
two major practical difficulties in applying VDD pacing mode in children: (1) with growth, 
atrial sensing is lost in many patients due to loss of contact between the atrial sensing 
electrode and the myocardium, and (2) only large diameter adult leads are available. 
Therefore, most centers have abandoned this pacing technique in children. 
4.5 Specific considerations in selecting single or dual chamber device 
4.5.1 Ventricular dysfunction 
An important consideration in selecting a pacing system is the presence of ventricular 
dysfunction. The ventricular dysfunction may worsen when a child receives a single 
chamber device. Therefore, a dual chamber system should be selected in patients with 
ventricular dysfunction with or without congenital heart disease. 
4.5.2 Single ventricle morphology and Fontan palliation 
Specific considerations are required for permanent pacing systems in patients after the 
Fontan procedure. Currently, the Fontan operation is the surgical approach of choice for 
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children with single ventricle physiology (Barber et al., 2005). Sinus node dysfunction and 
complete AV block are common indications for permanent pacing in patients after Fontan 
palliation. Studies have estimated that approximately 10% of these patients need pacemaker 
insertion during follow-up (Barber et al., 2005; Cohen et al., 2001a). Due to the limitations in 
venous access to the heart after the Fontan procedure, most patients receive an epicardial 
pacing system (Cohen et al., 2001a). Although various pacing modes have been described in 
these patients (Warfield et al., 1999), a recent haemodynamic study performed in the early 
postoperative period showed clearly that AV synchrony is vital in patients with Fontan 
physiology (Barber et al., 2005). Whether novel pacing techniques, such as multisite pacing 
to improve ventricular synchrony, have advantages over dual chamber pacing in these 
patients warrants further study. 
5. Selecting a pacing system: epicardial or endocardial pacing leads? 
Both transvenous and epicardial pacemaker leads are being used in paediatric patients with 
good early and long-term results. Because published guidelines on pacing indications in 
children and adults do not address selection of the type of pacing lead, choosing a 
transvenous or epicardial pacing lead depends on several considerations. An overview is 
presented on lead selection, the relative advantages of transvenous and epicardial pacing 
systems, complications and lead longevity. 
5.1 Anatomic considerations 
A unique aspect of pacing practice in children is that many patients have associated congenital 
heart disease. Coexisting anatomic vascular abnormalities in both surgically corrected and 
uncorrected congenital heart disease can influence the choice of the pacing lead system. 
Venous abnormalities associated with limited or difficult access to the heart include persistent 
left superior vena cava, various systemic venous abnormalities, single ventricle physiology 
after a modified Fontan procedure and presence of superior vena cava vein stenosis or 
obstruction in patients after Mustard or Senning operations for transposition of the great 
arteries. An epicardial lead system may be preferable in some of these patients. 
However, several options for alternative vascular access have been proposed in various 
types of corrected congenital heart disease (Gillette et al., 1986; Rosenthal et al., 1995; 
Adwani et al., 1997; Emmel et al., 2007). Pacing following the Fontan procedure for single 
ventricular physiology is usually accomplished using an epicardial lead system. Some 
authors have implanted endocardial pacing leads in the coronary sinus or using the 
transhepatic pathway in patients with a Fontan circulation (Rosenthal et al., 1995; Adwani et 
al., 1997). However, these techniques can be used only in a limited subset of patients with 
single ventricular physiology.  
Another example of transvenous lead implantation in a difficult venous anatomic setting is in 
patients with D-transposition of the great arteries palliated with a Mustard or Senning 
operation. Although progressive loss of sinus rhythm and sinus node dysfunction has been 
well documented in a significant proportion of patients following the Mustard or Senning 
operation, AV conduction abnormalities, higher-degree AV block and surgical complete AV 
block have also been noted at follow-up (Hayes & Gersony, 1986; Vetter et al., 1987). Superior 
vena cava obstruction appears postoperatively in 5 – 22% of patients with a Mustard or 
Senning type repair (Turley et al., 1988; Khairy et al., 2004). Because an obstruction in the 
venous pathway used for transvenous lead implantation can be present without signs and 
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symptoms, detailed venography, computerized tomographic scans or magnetic resonance 
imaging investigations are warranted in patients selected for an transvenous pacing system. 
When a venous stenosis or obstruction is encountered, implantation of a vascular stent may 
relief the stenosis, and allows implantation of a transvenous pacing system (Emmel et al., 
2007). The intermediate term results of the ‘stent-and-pace’ procedure are good. 
5.2 Intracardiac right-to-left shunting: a contraindication for transvenous pacing? 
Thrombus formation and paradoxical embolization may adversely affect patients with 
transvenous pacing systems. Although risk factors and data on the prevalence of thrombus 
formation on endocardial leads in children are lacking, several studies support the concept of 
paradoxical embolization (Silka & Rice, 1991; Johnson & Galindez, 1998; Barakat et al., 2000). A 
recent study identified the risk of systemic thromboemboli associated with transvenous pacing 
systems in adult patients with intracardiac shunts (Khairy et al., 2006). This study showed that 
patients with transvenous pacing systems and intracardiac shunts have a greater than two-fold 
increased risk of systemic thromboemboli. Of concern was that there was no apparent 
protective value of chronic aspirin or warfarin therapy in these patients. Independent risk 
factors for paradoxical systemic embolic events were older age, atrial fibrillation or flutter, and 
ongoing phlebotomy. A limitation of the study was that standardised methods for assessing 
right-to-left shunting were not uniformly adopted in all participating centers. 
The authors of this study suggested that efforts to eliminate right-to-left shunting should be 
pursued before transvenous pacing is applied, and if this may not be feasible, the epicardial 
pacing approach should be considered (Khairy et al., 2006). 
5.3 Endocardial or epicardial pacing system? 
The introduction of modern steroid-eluting bipolar leads has resulted in improved lead 
performance and survival of both epicardial and endocardial leads (Goldman-Cutler et al., 
1997; Johns et al, 1992; Udink ten Cate et al, 2002). The addition of steroid elution limits the 
inflammatory response at the electrode-tissue interface, resulting in better acute and chronic 
stimulation thresholds and improved battery longevity (Mond & Stokes, 1992). Both pacing 
lead systems offer effective pacing options in infants and children. Moreover, implantation of a 
transvenous or epicardial pacing system are safe and feasible procedures in most children. 
Although, the epicardial approach remains essential in children with congenital heart disease 
in whom venous access is not available, a transvenous lead system is most commonly 
advocated in children of adequate size (Fortescue et al., 2004; Kammeraad et al., 2004). 
An endocardial pacing system is preferably implanted in children weighing more than 15 kg 
(Fortescue et al., 2004; Alexander 2004), although implantation at a smaller patient size has 
been reported (Kammeraad et al., 2004; Sachweh et al., 2000). Several patient and lead 
related features should be weighed before an optimal decision regarding an epicardial or 
endocardial lead system can be made. 
Advantages of the epicardial approach include the avoidance of vascular injury and risk of 
venous occlusion, absence of lead problems associated with somatic growth, and no risk of 
endocarditis (Cohen et al., 2001b; Fortescue et al., 2004). Moreover, a dual chamber device 
can be implanted more easily in small children with or without congenital heart disease 
using the epicardial approach. Transvenous pacing systems offer the advantages of 
avoidance of a surgical procedure (thoracotomy or sternotomy), excellent lead survival, and 
lower acute and chronic pacing thresholds, and thereby increased battery longevity 
(Kammeraad et al., 2004; Udink ten Cate et al., 2002). 
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Major concerns regarding epicardial and endocardial lead systems include lead survival in 
epicardial leads, and risk of venous thrombosis and long-term vascular integrity after 
endocardial lead placement (Cohen et al., 2001; Kammeraad et al., 2004). Although modern 
steroid-eluting epicardial leads offer acceptable acute and chronic performance, they are 
prone to exit-block or non-capture due to high thresholds at the lead tip (Alexander, 2004). 
Several possible reasons for epicardial lead failure have been suggested, such as recurrent 
minor traumas imposed on the leads due to the active lifestyle of children (Figure 2), and 
presence of scarred epicardium after surgery for congenital heart disease (Silvetti et al., 
2007b). Current lead survival is 90% at 2 years after implantation, and 74% at 5 years for 
epicardial leads. A recent study showed a 5-year lead survival of 90% for endocardial leads 
(Fortescue et al., 2004). However, when a reanalysis was made of all leads placed in children 
who were less than 1 year of age at implant, the estimated 2-year and 5-year endocardial 
lead survivals were 90% and 78%, respectively. 
Endocardial lead systems carry a significant risk of venous thrombosis in infants and small 
children. The concern of venous patency in children who need life-long pacing has been an 
argument for a more conservative approach of selecting a lead system, preferring the 
epicardial approach (Bracke et al, 2003; Bar-Cohen et al., 2006). 
Complete venous obstruction has been documented in 11 – 21% of children at medium-term 
follow-up (Bar-Cohen et al., 2006; Figa et al. 1997, Kammeraad et al., 2004). Partial venous 
obstruction may be seen in another 12% of children receiving an endocardial pacing system  
 
 
Fig. 2. In the example above, a 12 year old active boy presented with acute failure of the 
atrial lead 5 years following upgrade from single chamber to dual chamber pacing. The 
original ventricular lead had been partially abandoned in the heart. The atrial lead clearly 
shows a fracture, probably related to lead compression stress between the clavicle and the 
first rib. Four weeks later, the ventricular electrode had also failed, and he presented with a 
junctional escape rhythm at a rate of 35 to 40 beats per minute. The leads were entirely 
removed using a combined subclavian and femoral venous approach, and a new DDD 
system was implanted via the left subclavian vein, using 2 thin lumenless leads. 
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at young age. The location of thrombosis varied throughout the venous anatomy, with most 
venous obstruction occurring in the left innominate vein (Bar-Cohen et al., 2006). However, 
not all studies found venous obstruction in children after endocardial pacing (Gillette et al., 
1988). 
Venous thrombosis is most often asymptomatic (Bar-Cohen et al., 2006; Kammeraad et al., 
2004). Nevertheless, it may cause superior vena cava syndrome in some patients. An 
important corollary, particularly in young patients requiring future lifelong pacing, is that 
every effort must be made to remove and replace nonfunctional leads in the vascular 
system. This often means the use of a variety of extraction systems, and occasionally 
transcatheter recanalization of stenosed or occluded vessels. 
Risk factors for venous thrombosis are not yet known. A recent study showed that patient 
age, body size, and lead characteristics at implant did not clearly predict venous occlusion 
(Bar-Cohen et al., 2006). However, an earlier study concluded that if the lead size indexed to 
body surface area was more than 6.6 mm2/m2, venous thrombosis could be predicted with 
a sensitivity of 90% and specificity of 84% (Figa et al, 1997). The recent development of a 
lumenless 4.1 F endocardial lead is a promising new lead design, which may decrease the 
risk for venous occlusion in children (Chakrabarti et al., 2009). 
In summary, many arguments exist for and against the use of epicardial or endocardial 
pacing systems in different subgroups of paediatric patients. In general, most neonates and 
small infants weighing < 10 kg receive initially an epicardial pacing system. At subsequent 
generator replacement, and depending on the child’s size, an endocardial pacing system 
may be implanted. 
5.4 Patient size and somatic growth issues in children 
Transvenous pacing implantation in children requires special attention to their amazing 
somatic growth potential. It has been estimated that approximately 190 mm of additional right 
ventricular pacing lead in infants and 100 mm in 10-year-old children is needed to enable 
growth to adulthood (Gheissari, et al., 1991). Moreover, an 80-mm right atrial lead loop will 
allow 6 to 12 years of growth in infants and older children (Sanjeev & Karpawich, 2006). 
To enable safe future growth in children with reliable transvenous single or dual chamber 
pacing, an additional amount of lead can be advanced into the heart during pacemaker 
implantation. Several options for creating such a redundant lead loop have been described 
(Rosenthal et al., 1997b; Gasparini, et al., 2000). A redundant lead loop may be placed in the 
right atrium or in the inferior vena cava. An example of a redundant lead loop in the inferior 
vena cava is shown in Figure 3. 
If necessary, additional lead can be advanced during an elective pulse generator 
replacement. When transvenous pacing is applied in neonates or small infants, the length of 
the redundant lead loop is insufficient for most of these patients to grow into adulthood. 
Elective lead advancement is often needed. Lead advancement during the first 2 years after 
pacemaker implantation was necessary in 4/36 (11%) infants weighing < 10 kg who 
received transvenous leads (Kammeraad et al., 2004). In one of these, lead advancement 
failed and the lead was replaced. 
5.5 Active or passive lead fixation 
A stable position of the lead tip is pivotal to provide excellent acute and chronic thresholds 
and lead performance. The development of passive and active fixation mechanisms has 
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Fig. 3. Posteroanterior chest X ray of a child with congenital complete atrioventricular block 
who received a single chamber transvenous pacing system after developing bradycardia-
related symptoms. The child’s weight was 12 kg. A redundant lead loop for future somatic 
growth was placed in the inferior vena cava. 
resulted in a tremendous reduction of the need for lead repositioning during follow-up 
(Furman et al., 1979). Passive fixation leads can be used for lead placement in the right 
ventricular apex. These leads can be easily positioned within the trabeculae of the right 
ventricle. The chronic pacing thresholds of passive fixation leads tend to be slightly better 
than those of active fixation leads (Hidden-Lucet et al., 2000). A disadvantage of passive 
fixation leads is that future lead extraction and replacement are more difficult, and this is an 
important issue in children (Hidden-Lucet et al., 2000). 
Active fixation leads, usually equipped with a screw-in helix mechanism can be fixed more 
easily at almost any position in the atrium and ventricle, making this lead type ideal for 
selective site pacing (Chakrabarti et al., 2009). Active fixation may also prevent lead 
displacement when a redundant atrial loop is used, which is again of particular relevance to 
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young children (Rosenthal & Bostock, 1997). In specific anatomic situations, such as 
transvenous pacing after the Mustard or Senning procedure, where the leads have to be 
securely positioned at unusual anatomic sites, active fixation is preferable. 
 
 
Fig. 4. The chest x ray shows an active fixation lead implanted in the roof of the native left 
atrium in a young patient who had undergone a Mustard operation for palliation of 
transposition of the great arteries. 
5.6 Unipolar and bipolar leads 
Epicardial and endocardial leads are available in unipolar or bipolar electrical 
configurations (Breivik et al., 1982; Breivik, et al., 1983; Mond, 1991). In general, the external 
diameter of a unipolar lead is usually smaller, because each coil is separated using 
insulating material. Although unipolar epicardial leads are still being used in paediatric 
pacing practice, most modern endocardial leads have a bipolar electrical configuration 
(Udink ten Cate et al., 2002). 
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The advantages of the unipolar lead configuration are lower pacing impedance, smaller size, 
and better lead survival and probably pacemaker longevity. With recent advances in lead 
design, the differences in pacing longevity between unipolar and bipolar lead systems have 
become marginal (Breivik et al., 1983; Mond, 1991). In addition, the lead diameter of bipolar 
leads has significantly decreased. Pectoral muscle stimulation, which may occur in unipolar 
pacing systems, is not often encountered in bipolar pacing systems. Bipolar leads are also 
less likely to detect far-field signals and electromagnetic interference (Mond, 1991). 
6. Pacing and lead complications in children: implications for follow-up 
6.1 Lead fractures, dislodgements, non-capture and insulation breaks 
Possible mechanisms of epicardial and endocardial lead failure include lead fracture, 
dislodgement, high thresholds and insulation break. A recent retrospective study of 1007 
implanted epicardial and endocardial leads in children with and without congenital heart 
disease requiring permanent pacing therapy found that lead fracture and exit-block were 
common complications seen with epicardial leads, whereas insulation breaks and lead 
dislodgements occurred more frequently in transvenous pacing systems (Fortescue et al., 
2004). In this study, 15% of the leads failed during follow-up, affecting 23% of the patients. 
Of these patients, 28% experienced multiple lead failures. The most common lead failure 
types were lead fracture and insulation break. The rates of lead failure are in accordance 
with those noticed in several other studies, reporting lead failure rates ranging between 2 – 
28% of implanted leads (Sachweh et al., 2000; Cohen et al., 2001b; Udink ten Cate et al., 2002; 
Bakhtiary et al., 2007; Welisch et al., 2010). Lead longevity of epicardial pacing systems were 
lower in most studies (Sachweh et al., 2000; Udink ten Cate et al., 2002; Fortescue et al., 2004; 
Welisch et al., 2010). 
Risk factors for lead failures in children may include younger age at implant and presence of 
congenital heart disease (Fortesue et al., 2004). Epicardial pacing leads are associated with a 
higher risk of lead failure. An explanation for these findings is that children undergo rapid 
linear growth and are more physically active than adults, thereby placing additional stress 
on the pacing lead system and increasing the risk for lead failure. 
Interestingly, it has been observed that only a minority of children (8%) report symptoms of 
pacing lead failure (Fortescue et al., 2004). Symptoms included skeletal muscle stimulation, 
palpitations, dizziness, or syncope. The remainder of patients were found to have 
pacemaker lead failure during regular pacemaker interrogation, routine chest radiography, 
or intraoperative lead examination. Routine and regular pacemaker follows up and 
interrogation are of upmost importance for optimal patient care. 
6.2 Pacemaker pocket infections and endocarditis 
Although pacemaker infections are uncommon in the paediatric population, deep pocket 
infection and pacemaker endocarditis are serious and life-threatening complications. When 
pacemaker-related infections occur, removal of the infected pulse generator and pacing leads 
are often required for infection control (Klug et al., 1997). Infections may be divided into 
superficial cellulitis, pocket infection, and endocarditis (defined as positive blood cultures). 
Pacemaker-related infections may develop in children before hospital discharge, or during 
early follow-up. Early pacemaker infections probably result from wound contamination 
during implantation (Cohen et al., 2002). In one paediatric retrospective study, the incidence of 
pacemaker-related infection was 7.8% for the whole cohort. The incidences of superficial 
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cellulitis, deep pocket infection and pacing lead infection were 4.9%, 2.3%, and 0.5%, 
respectively (Cohen et al., 2002). The authors concluded that the incidence of deep pocket 
infections was similar to those seen in adult studies (Kiviniemi et al., 1999; Klug et al., 1997), 
while more superficial infections occurred in their paediatric cohort. Moreover, Down 
syndrome was identified as an independent risk factor for pacemaker related infections. 
Patients with Down syndrome were 4 times as likely to develop an infection. The more severe 
pacemaker-related infections are most often seen following revision of a pulse generator with 
or without pacemaker lead exchange (Cohen et al., 2002; Fortescue et al., 2004). 
Most superficial infections can be managed with (intravenous) antibiotic therapy alone. 
Appropriate management of deep pocket infections and pacemaker lead infection, or 
endocarditis, involves complete removal of the entire pacemaker system and long-term 
intravenous antibiotic therapy. With aggressive and appropriate therapy, mortality rates in 
children with pacemaker infection are minor. A subpectoral pocket may be preferable for 
transvenous pacing systems in children, because infection seems to be less likely (Gillette et 
al., 1991; Cohen et al, 2002). 
6.3 Postpericardiotomy syndrome after pacemaker implantation 
Postpericardiotomy syndrome (PSS) is a well known complication after cardiac surgery. It has 
been observed in 10 – 50% of patients following open heart procedures (Miller et al., 1988). PPS 
may also occur after pacemaker implantation (Polin et al., 2006). PPS occurs in 2 – 6% of 
children following initial pacemaker implantation of both epicardial and transvenous lead 
systems (Udink ten Cate et al., 2002; Zeltser et al., 2004). Acute PPS may also develop after a 
subsequent lead revision in a small subset of children (Zeltser et al., 2004). Patients typically 
present with respiratory distress, chest pain, fever, and lethargy. Cardiovascular compromise 
was often seen. Most PPS episodes occurred within 14 days after pacemaker placement 
(Zeltser et al, 2004). In some instances, PPS may have a late onset (Spindler et al., 2001). 
PPS can be successfully managed with medical therapy that includes both anti-
inflammatory agents (NSAIDs) and diuretics. Pericardiocentesis is an option when 
cardiovascular compromise is present. The clinical outcome of PPS in children after 
permanent pacemaker implantation is excellent. 
6.4 Pacing induced ventricular remodelling and dysfunction 
The right ventricular (RV) apex has been the conventional site for endocardial ventricular 
pacing in children and adults (Karpawich, 2004). Recent studies have demonstrated that 
pacing from the RV apex may induce left ventricular dyssynchrony (Thambo et al., 2004; Tops 
et al., 2007; Cheng et al., 2009). It has long been recognized that ventricular dyssynchrony 
caused by a variety of cardiovascular diseases, including heart failure, ventricular 
preexcitation, and left bundle branch block mediate ventricular remodelling and subsequently 
myocardial dysfunction (Prinzen et al., 1995; Kass, 2008; Udink ten Cate et al., 2010a; Udink ten 
Cate et al., 2010b). Evidence is now emerging that pacing-induced ventricular dyssynchrony 
disturbs myocardial regional workload and wall stress, which may result in wall motion 
abnormalities, myocardial perfusion defects, changes in coronary blood flow, increased left 
ventricular cavity volume, and asymmetrical changes in left ventricular wall thickness 
(Karpawich, 2004; Kass, 2008; Cheng et al., 2009). Moreover, interstitial and cellular 
histopathological alterations have been demonstrated in the hearts of animals and patients 
after long-term right ventricular apical pacing (Karpawich et al., 1999; Cheng et al., 2009). 
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The concept of pacemaker-induced heart failure is particularly important when permanent 
pacing is applied to young children, who often need life-long pacing. Dilated cardiomyopathy 
may develop in 6 – 11% of paced children with autoimmune CCAVB during follow-up (Moak 
et al., 2001; Udink ten Cate et al., 2001; Kim et al., 2007). In addition, heart failure associated 
with prolonged pacemaker therapy was found in 46% of adolescents with repaired congenital 
heart disease (Nothroff et al., 2006). Although other risk factors may play an additional role in 
the pathogenesis of cardiomyopathy in these patients, pacing-induced LV dyssynchrony is an 
important but under-recognised contributor. 
6.4.1 Strategies to minimize ventricular pacing 
Identification of risk factors for pacing-induced cardiomyopathy, unravelling its pathogenesis, 
and developing pacing strategies to avoid the adverse effects of right ventricular apical and 
lateral wall pacing are crucial. The detrimental effects of pacing on right ventricular function 
are in part related to the cumulative percentage of ventricular pacing (Sweeney et al., 2005). An 
infant in whom the right ventricle is paced for 100% of the time is at a higher risk for 
developing ventricular dysfunction compared to an infant who is only paced for 50% of the 
time. This has prompted the search for novel pacing strategies that reduce unnecessary 
ventricular pacing, and thereby reducing the cumulative percentage of ventricular pacing 
(Kaltman et al., 2008; Sweeney et al., 2004). 
Managed ventricular pacing (MVP) and AAISafeR modes are new pacing algorithms 
designed for reducing cumulative percentage of ventricular pacing, with established 
benefits in the adult population (Mansour et al., 2006; van Mechelen & Schoonderwoerd, 
2006). This pacing strategy requires the implantation of a dual chamber device, programmed 
in DDD or DDDR mode. Patients who have sinus node disease, second-degree AV block, or 
high-degree AV block with intermittent complete AV block are thought to benefit most of 
this pacing algorithm (Kaltman et al., 2008). 
MVP is an atrial based pacing mode (AAI or AAIR). It primarily paces the atrium and 
monitors the ventricle for loss of AV conduction. When no ventricular beats are sensed 
between two consecutive atrial sensed or paced beats, MVP automatically mode switches to 
DDD or DDDR backup pacing (Kaltman et al., 2008; Mansour et al., 2006). Adverse effects 
have been described in the adult population, including tachyarrhythmias, ventricular 
fibrillation and failure of mode switch to ventricular backup pacing (Mansour et al., 2006; 
van Mechelen & Schoonderwoerd, 2006). The experience with MVP in children is limited. 
There is one retrospective study evaluating the safety and effectiveness of MVP in reducing 
unnecessary ventricular pacing in a large group of children with various diseases, including 
congenital and acquired AV block (Kaltman et al., 2008). Congenital heart disease was 
present in 64% of the children in the study group. MVP was effective in reducing the 
cumulative percentage of ventricular pacing, and only 1 MVP-related adverse effect was 
reported. Frequent nonconducted atrial depolarizations were noted in a patient with 
intermittent AV block. No proarrhythmic effect of MVP was noted in this study. Although 
there are no large randomized prospective trials in paediatric patients, MVP seems to be a 
promising pacing strategy for a subgroup of children of AV block. 
6.4.2 Should right ventricular apical pacing be avoided in children at all cost? 
The important question which has arisen following recent reports of pacing-induced 
cardiomyopathy is: should permanent pacing from the RV apex (for transvenous systems) 
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or RV anterior free wall (for epicardial systems) be abandoned in children with complete AV 
block? This is not an easy question to answer. First, a large proportion of children are at risk 
of developing ventricular dysfunction due to pacing, not all of them develop heart failure. 
Several studies have been undertaken to assess the incidence of ventricular dysfunction in 
paced children with CCAVB, and to identify potential risk factors (Udink ten Cate et al., 
2001; Moak et al., 2006; Beaufort-Krol et al., 2007; Kim et al., 2007; Vatasescu et al., 2007; 
Gebauer et al., 2009). Most studies found an incidence of dilated cardiomyopathy and LV 
dilation in 6.0 to 13.4% of children after long-term pacing. Risk factors for development of 
dilated cardiomyopathy and LV dilation with ventricular dysfunction may include presence 
of anti-SSA/Ro – SSB/La antibodies, increased heart size at initial evaluation and the 
absence of pacemaker-associated normalization of left ventricular size during follow-up, 
prolonged QRS duration, and transvenous pacing location (RV apex and RV free wall worse 
compared to RV septum). The interpretation of these results is troublesome, because most 
studies involved small groups of patients. Interestingly, recent studies have demonstrated 
physiologically benefits of alternative site pacing, including RV septal, outflow tract, or 
Hisbundle pacing (Karpawich, 2004). The degree of pacing-induced LV dyssynchrony is 
lower with these pacing strategies. However, large clinical paediatric studies are needed to 
determine if selective RV pacing sites are superior to pacing the RV apex, which is still most 
frequently used in clinical practice. 
6.4.3 Echocardiographic follow-up of children with permanent pacemaker therapy 
Serial echocardiographic investigations are important in the management of children with 
permanent pacemaker therapy. Although shorthening fraction, left heart size and ejection 
fraction can be easily measured, these conventional echocardiographic parameters are not 
sensitive enough to identify paced children at risk for development of dilated 
cardiomyopathy at an early stage in the disease process. However, this should be the 
ultimate goal for selection of children who may benefit from upgrading their pacing system 
to DDD pacing, biventricular pacing or selective site pacing. Tissue Doppler 
echocardiography and speckle tracking imaging may be used for measuring LV 
dyssynchrony, regional and global ventricular function (Figure 5). When LV dyssynchrony, 
regional and global myocardial function deteriorates, we might be able to identify patients 
who are at the highest risk for development of dilated cardiomyopathy. Although more 
research work needs to be done, these new techniques may guide crucial improvements in 
the management of children with permanent pacing devices. 
7. Conclusions 
Pacing in children with congenital or acquired AV block is a safe and feasible therapy. 
Selecting an appropriate pacemaker system for a child with complete AV block remains 
challenging. Several patient-related and pacemaker-related issues should be considered, 
including patient size, cardiac anatomy, pacing indication, pulse generator capabilities and 
pacing lead characteristics. 
A single chamber pacemaker is the preferably initial pacing mode in young children with 
complete AV block and normal ventricular function. Early establishment of AV synchrony 
in the young patient with a structurally normal heart and normal ventricular function is not 
thought to be beneficial. Conversely, single chamber devices should not be implanted in 
children following the Fontan operation or with ventricular dysfunction. 
www.intechopen.com
 Modern Pacemakers - Present and Future 
 
108 
 
Fig. 5. This image shows a parasternal short-axis view at the mid-ventricular level of a child 
with permanent right ventricular pacing for congenital complete AV block. The ventricular 
walls are divided into six myocardial segments (farb-coded). During one cardiac cycle, the 
time to systolic peak radial strain can be measured. The time delay between the septal and 
posterior wall (yellow and purple arrows, respectively), a parameter of LV dyssynchrony is 
estimated. There is significant LV dyssynchrony in this patient (184 ms, normally the time 
delay is < 130 ms). In addition, there is an inhomogeneous pattern of radial strain, with 
severely reduced peak radial strain values for all myocardial segments. (Radial peak strain 
values are presented as positive values). 
Excluding children weighing less than 15 kg, transvenous pacing systems may be safely 
implanted in children with structurally normal hearts. Active fixation endocardial leads are 
preferred in most children. Epicardial pacing is preferred in neonates and small infants, or 
when coexisting congenital heart disease exists with difficult venous access of the heart. 
Pacemaker-induced ventricular dysfunction and adverse remodelling are of concern in 
children who need life-long pacing. Definitive risk factors are to be determined. The concept 
of pacemaker-induced heart failure will have important implications in the way we treat 
and manage children with permanent pacemakers, with selective site pacing being likely to 
play a more important role. 
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techniques, device related complications, interactions, limitations, and benefits (including the role of pacing
role in heart failure), as well as future prospects of cardiac pacing.
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